Related Experiment Video
Updated: Dec 2, 2025
09:28
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
19.5K
Neurokinin 3 receptor antagonists - prime time?
J K Prague1,2
1Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter Hospital, Exeter, UK.
Climacteric : the Journal of the International Menopause Society
|November 2, 2020
Summary
New treatments targeting the neurokinin B/NK3 receptor pathway offer effective relief for menopausal hot flashes. These NK3 receptor antagonists provide a promising alternative to hormone therapy for women experiencing vasomotor symptoms.
Area of Science:
- Reproductive endocrinology and neurobiology
- Pharmacology of novel therapeutics
Background:
- Vasomotor symptoms, including hot flashes and night sweats, significantly impact menopausal women's quality of life.
- Current treatments like hormone therapy have risks and contraindications, necessitating alternative solutions.
- The neurokinin B (NKB)/neurokinin 3 receptor (NK3R) pathway is implicated in the development of these symptoms.
Purpose of the Study:
- To evaluate the efficacy and tolerability of NK3 receptor antagonists for treating menopausal vasomotor symptoms.
- To explore a non-hormonal therapeutic option for managing hot flashes.
Main Methods:
- Clinical trials involving chemically distinct oral NK3R antagonists.
- Assessment of symptom reduction and side effect profiles.
Main Results:
- Consistent demonstration of efficacy across multiple clinical trials.
- Favorable tolerability profiles reported for NK3R antagonists.
- Significant reduction in the frequency and severity of hot flashes.
Conclusions:
- NK3 receptor antagonists are a promising, effective, and well-tolerated non-hormonal treatment for menopausal vasomotor symptoms.
- These agents may offer a safe alternative for women unable to use or seeking alternatives to hormone therapy.
- Further large-scale studies are warranted to confirm long-term efficacy and safety for widespread clinical adoption.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
401
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
401
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
478
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
478
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
677
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
677
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.5K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.5K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
956
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
956
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
954
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
954